Clinical trial / 2020
Erinacine A-enriched Hericium erinaceus mycelia capsules for 49 weeks improved cognitive scores and contrast sensitivity in patients with mild Alzheimer's disease.
Patients with mild Alzheimer's disease were randomized to receive three 350 mg erinacine A-enriched Hericium erinaceus mycelia (EAHE) capsules per day (5 mg/g erinacine A) or placebo for 49 weeks following a 3-week screening period. After 49 weeks, the EAHE group showed significant improvement in MMSE score, a significant difference in IADL score compared to placebo, and a significant decrease in CASI score was noted only in the placebo group. The EAHE group also achieved significantly better contrast sensitivity and showed differences in biomarkers and neuroimaging ADC values compared to placebo. Four subjects dropped out due to abdominal discomfort, nausea, and skin rash, with no other adverse events reported.
- Study type
- Pilot double-blind randomized placebo-controlled trial
- Who was studied
- Patients with mild Alzheimer's disease (sample size not stated; four dropped out due to adverse events)
- What was measured
- Cognitive scores (CASI, MMSE, IADL), contrast sensitivity, biomarkers, and neuroimaging (ADC values)
THE PAPER
Prevention of Early Alzheimer's Disease by Erinacine A-Enriched Hericium erinaceus Mycelia Pilot Double-Blind Placebo-Controlled Study.
Li IC, Chang HH, Lin CH, Chen WP, Lu TH, Lee LY, Chen YW, Chen YP, Chen CC, Lin DP. Front Aging Neurosci, 2020.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.